Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

[1]  Huldrych F. Günthard,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, JAMA.

[2]  H. Stellbrink,et al.  Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results , 2018 .

[3]  D. Schlossberg,et al.  VIREAD (Tenofovir Disoproxil Fumarate) , 2017 .

[4]  P. Harrigan,et al.  Emergent drug resistance with integrase strand transfer inhibitor-based regimens , 2017, AIDS.

[5]  B. Kearney,et al.  P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir , 2017 .

[6]  K. White,et al.  Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. , 2017, The lancet. HIV.

[7]  A. Winston,et al.  Psychiatric Symptoms in Patients Receiving Dolutegravir , 2017, Journal of acquired immune deficiency syndromes.

[8]  K. White,et al.  Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults , 2017, Journal of acquired immune deficiency syndromes.

[9]  H. Stellbrink,et al.  Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients , 2017, HIV medicine.

[10]  K. Brinkman,et al.  Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice , 2016, AIDS.

[11]  K. White,et al.  Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile , 2016, Antimicrobial Agents and Chemotherapy.

[12]  L. Ye,et al.  Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials , 2016, AIDS Research and Therapy.

[13]  Jennifer F Hoy,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. , 2016, JAMA.

[14]  D. Klein,et al.  Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals , 2016, Journal of acquired immune deficiency syndromes.

[15]  A. Mocroft,et al.  Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration , 2016, BMC Medicine.

[16]  E. Moodie,et al.  Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study , 2015, Journal of acquired immune deficiency syndromes.

[17]  D. Katzenstein,et al.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.

[18]  S. Piscitelli,et al.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults , 2011, AIDS.

[19]  M. Huque,et al.  A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV Submissions , 2011 .

[20]  O. Kirk,et al.  Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[21]  O. Kirk,et al.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. , 2010, The Journal of infectious diseases.

[22]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[23]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.